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Abstract
Angiotensin-I-converting enzyme (ACE) inhibitors are an important class of antihyper-
tensives whose action on the human organism is still not fully understood. Although it is
known that ACE especially cleaves COOH-terminal dipeptides from active polypeptides,
the whole range of substrates and products is still unknown. When analyzing the action
of ACE inhibitors, effects of genetic variation on metabolism need to be considered since
genetic variance in the ACE gene locus was found to be associated with ACE-concentra-
tion in blood as well as with changes in the metabolic profiles of a general population. To
investigate the interactions between genetic variance at the ACE-locus and the influence
of ACE-therapy on the metabolic status we analyzed 517 metabolites in 1,361 partici-
pants from the KORA F4 study. We replicated our results in 1,964 individuals from Twin-
sUK. We observed differences in the concentration of five dipeptides and three ratios of
di- and oligopeptides between ACE inhibitor users and non-users that were genotype
dependent. Such changes in the concentration affected major homozygotes, and to a
lesser extent heterozygotes, while minor homozygotes showed no or only small changes
in the metabolite status. Two of these resulting dipeptides, namely aspartylphenylalanine
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and phenylalanylserine, showed significant associations with blood pressure which qual-
ifies them—and perhaps also the other dipeptides—as readouts of ACE-activity. Since
so far ACE activity measurement is substrate specific due to the usage of only one oligo-
peptide, taking several dipeptides as potential products of ACE into account may provide
a broader picture of the ACE activity.
Introduction
Hypertension is a highly prevalent risk factor for the development of cardiovascular diseases
and atherosclerosis as well as for renal failure. Antihypertensive medication ranks among the
most frequently prescribed drugs in medical practice.
An important class of antihypertensive agents are angiotensin-I-converting enzyme (ACE)
inhibitors. ACE catalyzes the conversion of angiotensin-I to angiotensin-II which causes the
muscles surrounding blood vessels to contract, thereby restricting the blood flow and increas-
ing blood pressure. ACE inhibitors diminish the action of this enzyme and, thus, blood vessels
dilate and blood pressure is reduced [1, 2].
ACE acts not only on angiotensin I cleaving the dipeptide histidylleucine (His-Leu), but
also cleaves COOH-terminal dipeptides from several other active peptides [3]. These peptides
include for example the vasodilator bradykinin [4, 5], the neuropeptide cholecystokinin-8 [6],
which acts on the gastrointestinal system, different forms of the opioid peptide encephalin [7,
8] as well as the neuropeptides substance P and neurotensin [9]. While the whole range of sub-
strates and products is still unknown, it has been suggested that ACE, and thus ACE inhibitors,
might have a more general impact on biologically active peptides and subsequently on metabo-
lism than previously recognized [10, 11].
Applying a metabolomics approach, we recently investigated the effect of antihypertensives
on blood metabolomes in the general population by analyzing the association of ACE inhibitor
intake and metabolite levels in serum samples from the KORA (Cooperative Health Research
in the Region of Augsburg) study [12]. The analysis yielded several significant associations
with oligopeptides including des-Arg(9)-bradykinin and aspartylphenylalanine (Asp-Phe), a
substrate and a product of peptide cleavage catalyzed by ACE.
In recent genome-wide association studies with traits from high-throughput metabolite
screening (mGWAS), Asp-Phe and several other dipeptides had been found to associate with
single nucleotide polymorphisms (SNPs) in the ACE locus [13–15]. Though His-Leu was not
among the quantified metabolites, these findings are consistent with results from Chung et al.
[16], who reported that the same genetic variants influence the activity of ACE in blood as
measured through an assay that specifically targets the cleavage of p-hydroxyhippuryl-L-histi-
dyl-L-leucine. As a consequence, genetic factors could have potential implications for the indi-
vidual response to ACE inhibitor treatment and could also modulate the broader metabolic
effects of ACE inhibitors.
In this study we aimed to find genotype dependent differences in the metabolic response
to ACE inhibitor intake using metabolites as readout of the ACE inhibitor’s effect. To this
end, we used a mass spectrometry based non-targeted metabolomics approach that includes
measurements of several di- and oligopeptides. We analyzed the metabolic profiles of 1,361
participants from the KORA (Cooperative Health Research in the Region of Augsburg)
study and 1,964 individuals from the TwinsUK cohort. Using such a population based
approach provides the possibility to find hypotheses that reflect the drug response under
everyday life conditions.
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Methods
Study populations
The research platform KORA conducts population-based surveys and subsequent follow-up
studies in the fields of health care research, health economics, epidemiology and genetics. A
multitude of different parameters is provided, including medical history. Here, we analyzed a
dataset that was taken from the F4 study, which was conducted in 2006−2008 as a follow-up of
the fourth KORA survey (S4; 1999−2001). From this KORA F4 population, the metabolic pro-
files of 1,768 participants, aged between 32 and 77 years were measured. To determine the use
of medication participants were asked to bring all medications along with them, which they
had taken during the past 7 days preceding the interview. The medical staff registered the med-
ication data online using the IDOM software [17]. The drug classes, including the class “ACE
inhibitors”, were categorized according to the Anatomical Therapeutical Chemical (ATC) clas-
sification index recommended by the World Health Organization (WHO; http://www.whocc.
no/atc/structure_and_principles/). Out of the 1,768 KORA F4 participants 282 individuals
were ACE inhibitor users, while 1,079 individuals did not take any antihypertensives at all.
These 1361 individuals were used for analysis. The characteristics of ACE users vs. non-users
of any antihypertensive drugs are shown in S1 Table. A pie-chart of the agents within the class
“ACE inhibitors” is given in the S1 Fig.
The TwinsUK cohort is an adult UK twin registry composed of mostly women aged 18 to
85. Twins were recruited from the general UK population through national media campaigns
and were shown to have similar disease-related and lifestyle characteristics as population-based
singletons in the same age group [18]. The 1,964 individuals analyzed in this study were 99.7%
female in the age range of 23 to 84 years (mean of 58 years). In total, 166 ACE inhibitor users
and 1,798 individuals not on any antihypertensive treatments were included.
Informed written consent was obtained from each participant of both populations and all
study protocols were approved by the local ethics committees (Bayerische Landesärztekammer
for KORA and Guy’s and St. Thomas’Hospital Ethics Committee for TwinsUK).
Blood samples
For both populations, we collected blood serum of the study participants. To avoid variation
due to circadian rhythm, KORA blood samples were taken after overnight fasting (at least 8
hours) in the morning between 8 and 10:30 am. Medication was taken in the morning as usual.
After drawing the material into serum gel tubes, it was gently inverted twice and subsequently
rested 30 min at room temperature (18–25°C) to obtain complete coagulation. The material
was then centrifuged for 10 min (2,750g at 15°C). Serum was aliquoted and stored at 4°C, after
which it was deep frozen to -80°C on the same day until analysis of the metabolites.
For the TwinsUK study, blood was drawn after at least 6 h of fasting. The samples were
immediately inverted three times, followed by 40 min of resting at 4°C to obtain complete
coagulation. After centrifuging the samples for 10 min at 2,000g serum was collected. Four ali-
quots of 1.5 ml were placed into skirted microcentrifuge tubes and then stored at −45°C until
sampling.
Metabolite profiling and metabolite spectrum
The metabolite profiles were measured by the US-company Metabolon Inc., a commercial sup-
plier of metabolomic analyses. Their platform integrates the chemical analysis, including iden-
tification and relative quantification, data reduction, and quality assurance components of the
process. One gas chromatography/mass spectrometry (GC/MS) injection and two separate
Genotype and Metabolic Response to ACE Inhibitors
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ultrahigh performance liquid chromatography/tandem mass spectrometry (UHPLC/MS/MS;
positive and negative mode) injections were done on this platform.
The GC/MS platform utilized a Thermo-Finnigan Trace DSQMS, while for UHPLC/MS/
MS analysis a Waters Acquity UPLC and a ThermoFisher LTQ mass spectrometer were used.
A standard library containing retention time, molecular mass to charge ratio (m/z), preferred
in-source fragments and adducts as well as their associated MS/MS spectra for all molecules in the
library, subsequently allowed to identify a multitude of metabolites based on the measured spectra.
Metabolon applies an analytic approach which is semi-quantitative. This means that the
injected standards are not used to calculate the metabolite concentrations but mainly to deter-
mine the retention time. Thus, a relative intensity is measured and the measurement is sensitive
to instrument parameters as well as fluctuations caused by maintenances such as column change.
Since these fluctuations are run day dependent, a run day normalization of the metabolic data
was done: For each individual and each metabolite the data was first divided by the day median
of the respective metabolite and then multiplied for the overall median of this metabolite.
Metabolon showed that their analytical platform is able to perform relative quantitative analy-
sis of analytical data in a high-throughput mode and that it identifies a broad spectrum of mole-
cules with a high degree of confidence [19]. The measured panel includes 517 metabolites from
many relevant classes such as carbohydrates, acylcarnitines, glyceropospholipids, lipids, amino
acids, small peptides, cofactors and vitamins, nucleotides and xenobiotics. A third of these
metabolites, marked with an identifier starting with the letter “X” followed by five digits, are cur-
rently identified by their mass, and MS/MS fragmentation and chromatographic retention time,
but their biochemical identity is unknown. A list of all metabolites is given in the–S2 Table.
Genotyping and imputation
For all used samples from KORA, genotype information derived from the Affymetrix Axiom
Chip was available. Genotype calling was conducted with the Affymetrix Software and variant
annotation was carried out according to NCBI build 37. For quality control, we applied the cri-
teria of at least 97% call rate per person and 98% call rate per SNP, HWE (p-value5×10−6)
and a minor allele frequency of0.01. Pre-phasing was done with SHAPEIT v2. Imputation
was performed with IMPUTE v2.3.0 based on the 1000G phase1 (v3) reference panel.
Statistical analysis
For the statistical analysis the statistical analysis system R (http://www.r-project.org/) was used.
Besides the metabolite values, the ratios between the values of all possible pairs of metabo-
lites were used in the analysis. This metabolic data was inverse normalized since the metabolite
concentrations didn’t show a normal distribution. To avoid false-positive associations, data
points of metabolic traits that lay more than three standard deviations off the mean were
excluded from further analysis.
For the identification of relevant ACE-SNPs in KORA, we used the results of two former
studies on KORA individuals. In a systems approach combining genetic and metabolic infor-
mation to identify unknown metabolites, the ACE-SNP rs4343 showed several significant asso-
ciations with metabolite changes [20]. Another KORA study on human metabolic individuality
revealed rs4329 as an ACE-SNP influencing the metabotype [14]. Proxy SNPs for rs4343 and
rs4329 based on a linkage disequilibrium threshold of at least 0.9 (genome assembly: GRCh37;
variant set: 1000 Genomes, Phase 3 v5; genome annotation: Ensemble 77; http://snipa.org [21])
were also included in the analysis.
We did a two-step approach to test possible interactions between ACE-SNPs and ACE
inhibitor intake.
Genotype and Metabolic Response to ACE Inhibitors
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In the first analysis step a linear regression test with cofactors age and sex was used to model
the association of each metabolite and metabolite ratio with each of the 25 ACE-SNPs (assum-
ing an additive genetic model). The linear regression tests were separately applied for ACE
inhibitor users and individuals not taking any antihypertensives (non-users). To control for
the effect of testing multiple hypotheses we used the Bonferroni correction. Thus, only associa-
tions with a p-value smaller than 1.4x10-8 (0.05/(517(517/2) metabolite ratios + 517 metabo-
lites)/25 SNPs) and with a p-gain greater than 517 (for ratios) were considered as significant.
The p-gain is a measure to determine whether the ratio between two metabolite concentrations
carries more information than the two corresponding metabolites alone [22].
Metabolites and metabolite ratios with significant associations were only found for the group
of non-users, while the corresponding tests in the group of ACE inhibitor users were not signifi-
cant. Based on this result we investigated if genotypes in the non-users group showed metabolite
concentrations that were significantly different from the metabolite levels of all ACE inhibitor
users. Thus, in a second analysis step we applied a linear regression test to each genotype group
of the non-users to compare their metabolite levels with those of all ACE inhibitor users.
Metabolites with significant differences between a genotype group of non-users and all
users were tested for replication in the TwinsUK population. From the three candidate ratios
only aspartylphenylalanine/HWESASXX was available in the replication cohort as for the
remaining ratios were not in the TwinsUK metabolomics data set. As in KORA all ACE-SNPs
showed the same effect, we only attempted to replicate the SNP rs4329. For TwinsUK we used
linear mixed-effects models to account for familial relationship.
Results
Genotypes at the ACE-SNPs only affect peptide levels in non-users
In a first step, we analyzed the KORA F4 metabolite data for associations with the ACE-SNPs
separately for ACE inhibitor users and participants who did not take any antihypertensives
(non-users). As an example, the results for ACE-SNP rs4329 are given in Table 1.
Boxplots and results for all other analyzed ACE-SNPs can be found in S1 Text and S3 Table.
Significant associations with the ACE-SNPs could only be found in the analysis of the non-
users. The dipeptides aspartylphenylalanine (Asp-Phe) (Fig 1), X14086 (possibly threonylgluta-
mate), α-glutamyltyrosine (α-Glu-Tyr, formerly X14205), phenylalanylserine (Phe-Ser, for-
merly X14208) and leucylalanine (Leu-Ala, formerly X14304, negative mode (and X14189
positive mode)) were all negatively associated with the ACE-SNPs. Likewise, the metabolite
ratios Asp-Phe/HWESASXX, Asp-Phe/X11805 and Asp-Phe/phenylalanylleucine (Phe-Leu,
formerly X14450) showed negative associations with these SNPs. The oligopeptide HWE-
SASXX is a part of the factor C3f which is degraded from C3 complement. The p-values of all
significant results for the example rs4329 ranged from 6.04x10-11 to 9.16x10-28. P-gains from
1133.158 to 6.60x1016 indicate that these ratios carry more information than the two corre-
sponding metabolites alone. Using additional cofactors, such as BMI, HDL cholesterol, LDL
cholesterol, total cholesterol, triglycerides, diabetes and hypertension in the linear regression,
or using the inversed ratios yielded the same significant associations.
Differences in peptide levels between non-users and users depend on
genotype
These metabolites and metabolite ratios with significant genetic associations in the non-users
were analyzed in a second step to elucidate if genotype groups of the non-users differ signifi-
cantly from all ACE inhibitor users. The results of this analysis (Table 1) showed that the
Genotype and Metabolic Response to ACE Inhibitors
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metabolite concentrations of major homozygous (genotype AA) as well as heterozygous (geno-
type AG) non-users were significantly different from the metabolite concentrations of the
users. Looking at the consistently negative beta estimates for every metabolite separately, a
clear decreasing trend could be observed: the absolute beta value of the major homozygotes
was always higher than the one of the heterozygotes which was in turn higher than the absolute
beta value of the minor homozygotes. This trend was observed for all ACE-SNPs.
Fig 1. Inverse normalized values of aspartylphenylalanine for KORA and TwinsUK (AA: major homozygotes, AG: heterozygotes, GGminor
homozygotes).
doi:10.1371/journal.pone.0153163.g001
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Replication in TwinsUK
The metabolites and metabolite ratios showing significant associations with the ACE-SNPs in
the KORA non-users were used for replication in TwinsUK (Table 2; S2 Text).
For three metabolites–Asp-Phe, Leu-Ala (X14304 and X14189) and Phe-Ser–and the ratio
Asp-Phe/HWESASXX, the effect observed in KORA could be replicated. All five metabolite
traits are significantly associated with the ACE-SNP rs4329 in non-users with p-values ranging
from 2.15 x10-06 to 3.80x10-10, while in ACE inhibitor users no such association could be
found.
Consistent with the KORA findings, also their concentrations in major homozygous (geno-
type AA) as well as in heterozygous (genotype AG) non-users were significantly different from
the concentrations in the users–except for Phe-Ser, which showed only a significant association
in the major homozygotes. The decreasing trend indicated by the beta estimates could not only
be observed for the three metabolites with significant associations, but for all analyzed candi-
date metabolites.
Significant association with blood pressure
To investigate whether the resulting metabolites are connected to blood pressure we applied a
linear regression model with cofactors age and sex.
Asp-Phe shows a significant positive association with diastolic (p-value: 0.002) as well as
systolic blood pressure (p-value: 0.009) in individuals not on antihypertensive treatment (non-
users). Thus, with higher circulating levels of Asp-Phe a higher blood pressure is observed.
Likewise, Phe-Ser is positively associated with diastolic (p-value: 0.001) as well as systolic (p-
value: 0.005) blood pressure.
Discussion
In this study we investigated genotype dependent differences in the metabolic response to ACE
inhibitor intake. To this end, 517 serum metabolites of 1,361 participants from the population-
based KORA F4 cohort were analyzed. For several di- and oligopeptides, we found significant
influences of genetic variants in the ACE locus on the metabolites’ blood concentrations for
individuals not treated with antihypertensives (non-users), whereas this effect was not
Table 2. Replication results from the TwinsUK study for rs4329.
metabolic trait n (non-
users)
beta
(non-
users)
p-value
(non-users)
n
(users)
beta
(users)
p-value
(users)
n
AA
beta
AA
p-
value
AA
n
AG
beta
AG
p-
value
AG
n
GG
beta
GG
p-
value
GG
aspartylphenylalanine 574 -0.436 3.80x10-10 56 -0.017 0.939 174 -0.764 0.0001 279 -0.464 0.005 121 -0.059 0.731
aspartylphenylalanine /
HWESASXX
574 -0.233 2.15x10-06 56 -0.158 0.308 174 -0.441 0.001 279 -0.269 0.018 121 -0.090 0.439
X14086 486 -0.130 0.046 46 -0.321 0.209 143 -0.181 0.298 240 -0.076 0.648 103 0.075 0.680
leucylalanine (X14189)
pos. mode
510 -0.308 8.58 x10-07 47 0.036 0.879 152 -0.792 2.19
x10-05
248 -0.756 6.03
x10-06
110 -0.218 0.184
α-glutamyltyrosine
(X14205)
169 -0.180 0.113 4 0.242 0.877 61 -0.498 0.379 84 -0.341 0.491 24 0.205 0.653
phenylalanylserine
(X14208)
408 -0.408 9.75 x10-08 15 0.059 0.892 131 -0.697 0.014 194 -0.415 0.121 83 0.232 0.439
leucylalanine (X14304)
neg. mode
488 -0.302 3.58 x10-06 48 0.094 0.628 147 -1.017 1.76
x10-07
237 -0.961 4.62
x10-08
104 -0.408 0.015
For column description see Table 1; due to the family structure linear mixed-effects models were used instead of linear regressions; data for the ratios
aspartylphenylalanine/X11805 and aspartylphenylalanine/phenylalanylleucin (X14450) was not reported in TwinsUK.
doi:10.1371/journal.pone.0153163.t002
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observable in subjects medicated with ACE inhibitors (users). Moreover, significant effects on
the levels of these metabolites through intake of ACE inhibitors can only be reported for indi-
viduals with major homozygous or heterozygous genotypes for ACE variants tagged by rs4329.
Please note that this is a cross-sectional study which—in contrast to a longitudinal approach—
observes no intra-individual changes. The results for the dipeptides aspartylphenylalanine
(Asp-Phe), leucylalanine (Leu-Ala) and phenylalanylserine (Phe-Ser) as well as for the ratio
Asp-Phe/HWESASXX could be replicated in the independent TwinsUK cohort proving the
robustness of our results. In the following, we discuss specific hypotheses that can be generated
from our findings and that might give useful hints for personalized treatment of hypertension.
Analyzing several dipeptides as potential products of ACE at once provides a broader picture
of the ACE activity than focusing only on the cleavage of angiotensin. Hence, we found hints
for genotype dependent shifts in the activity of ACE regarding different substrates.
Dipeptides as potential functional markers of ACE activity
Besides angiotensin I and II, ACE metabolizes a multitude of different substrates. Cholecysto-
kinin-8 (CCK-8) is one substrate of ACE from which the dipeptide Asp-Phe-NH2 is cleaved
[6]. Consistent with an inhibition of this process, in a former KORA study we observed lower
levels of Asp-Phe in ACE inhibitior users [12]. This means, that the dipeptide Asp-Phe as a
product of this cleavage process can be considered as a functional marker for ACE activity.
Our observation of a significant positive association between Asp-Phe and the diastolic
blood pressure strengthens this suggested role of Asp-Phe as a functional marker for ACE
activity.
When the data was stratified by ACE genotype (second analysis step), it turned out that
only homozygotes of the rs4329 ACE major allele, and to a lesser extent also heterozygotes, dis-
played lower Asp-Phe concentrations in treated individuals when compared to non-treated
ones. For the homozygotes of the minor allele, the Asp-Phe concentration did not show signifi-
cant differences between ACE inhibitor users and non-users. Thus, Asp-Phe concentration,
which was found to be connected to blood pressure, was not affected by the intake of ACE
inhibitors in homozygotes of the minor allele. This suggests, that these patients might not fully
profit from the effect of the ACE inhibitor.
Similar to Asp-Phe, four other dipeptides, namely Leu-Ala, α-Glu-Tyr, Phe-Ser and the
unknown metabolite X14086 (probably threonylglutamate), showed genotype dependent rela-
tive differences in the metabolic concentration between individuals using ACE inhibitors and
non-users. Though only for Phe-Ser a significant association with blood pressure could be
observed in our KORA analysis, these four dipeptides might work as functional markers for
genotype dependent ACE activity or shifts in its substrate specificity. For example, Phe-Ser is
included in the amino acid sequence of bradykinin, a known substrate of ACE which plays a
role in the decrease of blood pressure [4, 5].
Ratios indicate possible shifts in ACE substrate specificity
The opioid Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) is known to be degraded by ACE by release
of Phe-Leu [7, 8]. As many opioid peptides Leu-encephalin is suggested to be involved in the
cardiac metabolism [23]. Since we observed a negative association with ACE inhibitor intake
for this ratio (beta: -0.150, p-value: 2.75x10-29, p-gain: 2.68x1013), we hypothesize that in indi-
viduals using ACE inhibitors the Leu-enkephalin degradation releasing Phe-Leu is relatively
increased compared to the cleavage of CCK-8 releasing Asp-Phe. We might further speculate
whether ACE inhibitors rather interfere with the cleavage of CCK-8 than of Leu-enkephalin. A
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possible beneficial effect of CCK-8 was reported by Ahren et al. [24] who showed that CCK-8
exerts an antidiabetogenic action by stimulating insulin secretion.
When stratified by ACE genotype the ratio Asp-Phe/Phe-Leu also shows the effect that only
homozygotes of the major allele, and to a lesser extent heterozygotes, display lower concentrations
in ACE inhibitor users when compared to non-user. With this result, the question arises if these
major homozygotes and heterozygotes might be more affected by possible side-effects (whether
favorable or not) caused by a shift towards a possibly preferred cleavage of Leu-enkephalin.
Besides Asp-Phe/Phe-Leu, also the ratios Asp-Phe/HWESASXX and Asp-Phe/X11805
show the genotype dependent decreasing trend in non-users.
HWESASXX is a part of the factor C3f (NH2-Ser-Ser-Lys-Ile-Thr-His-Arg-Ile-His-Trp-
Glu-Ser-Ala-Ser-Leu-Leu-Arg- COOH) [25], a degradation product of C3b which is itself lib-
erated during the cleavage of the C3 complement [26, 27]. C3 is one of several proteins in the
complement system that plays an important role in the human immune response. However, an
over-activation of its proteins was found to be involved in the development of many different
diseases [28]. Based on the analysis of C3-deficient mice Zhou et al. suggested that “C3 may be
a primary factor to activate the renal RA [renin-angiotensin] systems to induce hypertension”
[29],Muscari et al. identified in a population study C3 as a predictor of myocardial infarction
in men [30], and Engström et al. found that C3 is associated with the risk of developing hyper-
tension [31]. The fragment C3f was observed to induce spasms and to increase vascular perme-
ability in the skin of guinea pigs [26]. A suggested connection between angiotensin and the
complement system/inflammation is not fully understood so far [32].
In our study the genotype dependent differences in the ratio Asp-Phe/HWESASXX between
ACE inhibitor users and non-users, implicate that for major homozygotes and (to a lesser
extent) heterozygotes the relation of Asp-Phe and HWESASXX in the blood changes with the
intake of ACE inhibitors. Thus, these groups might be more affected by advantages or disad-
vantages that may come with a shift towards a decreased cleavage of CCK-8 and a hypothesized
increase in C3f degradation.
From the unknown X11805 in the ratio Asp-Phe/X11805 it is only known that it is an oligo-
peptide. One may speculate if it might be a product of ACE, but more insight in possible effects
of a genotype dependent shift of this ratio has to be postponed until X11805 is identified.
Limitations
Both study populations were composed of Caucasians of European ancestry, which means that
our results cannot be generalized to other ethnicities. Since ACE activity was not directly mea-
sured and because of the cross-sectional design of this study, we can only generate hypotheses
based on associations.
For our analysis we created the drug class “ACE inhibitor” to increase the statistical power.
Thus, it is not possible to trace the observed effects on the metabolism back to single pharma-
ceutical agents. However, significant associations could be clearly observed using this drug
class.
The dipeptide His-Leu cleaved from the most prominent ACE substrate angiotensin I was
not among the significant associations. We may speculate if it is one of the unknown metabo-
lites (starting with “X”) and does not show any significant changes due to further regulation
mechanisms. On the other hand it might just not been detected by the used analytical method.
Conclusion
In summary, we could identify several di- and oligopeptides that show genotype dependent dif-
ferences in their concentration between ACE inhibitor users and non-users (Fig 2). Such
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changes in the concentration affected major homozygotes, and to a lesser extent heterozygotes,
while minor homozygotes showed no or only small changes in the metabolite status. The sig-
nificant associations of aspartylphenylalanine and phenylalanylserine with blood pressure
showed that our results are connected to blood pressure. This means that these two dipeptides
and perhaps also the other resulting metabolites might be markers for ACE activity. Thus,
depending on the respective genotype, it might be worth considering an alternative drug for
hypertension medication with respect to efficacy as well as side effects possibly induced by a
shift in ACE substrate specificity.
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